Stephen J. Mcandrew Sells 15,705 Shares of Oncobiologics Inc (ONS) Stock
Oncobiologics Inc (NASDAQ:ONS) SVP Stephen J. Mcandrew sold 15,705 shares of the stock in a transaction dated Friday, December 22nd. The shares were sold at an average price of $1.13, for a total transaction of $17,746.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Oncobiologics Inc (NASDAQ:ONS) traded down $0.01 during trading hours on Thursday, reaching $1.16. 81,900 shares of the company’s stock traded hands, compared to its average volume of 110,109. The company has a debt-to-equity ratio of -0.01, a quick ratio of 0.03 and a current ratio of 0.03. The stock has a market cap of $29.17 and a price-to-earnings ratio of -0.63. Oncobiologics Inc has a 52-week low of $0.78 and a 52-week high of $3.95.
A hedge fund recently raised its stake in Oncobiologics stock. Sabby Management LLC lifted its stake in shares of Oncobiologics Inc (NASDAQ:ONS) by 5.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,365,763 shares of the company’s stock after purchasing an additional 127,293 shares during the period. Sabby Management LLC owned 9.59% of Oncobiologics worth $2,371,000 at the end of the most recent quarter. 18.52% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This article was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://theolympiareport.com/2017/12/28/stephen-j-mcandrew-sells-15705-shares-of-oncobiologics-inc-ons-stock.html.
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.